A3921104

Polyarticular course Juvenile Idiopathic Arthritis (including systemic JIA with active arthritis but without active features), enthesitis-related arthritis and psoriatic arthritis.

The aim of the study:

The efficacy, safety and tolerability of tofactinib to placebo in pediatric patients 2 to <18 years of age with polyarticular course Juvenile Idiopathic Arthritis (including systemic JIA with active arthritis but without active features), enthesitis-related arthritis and psoriatic arthritis.

How long is the study?

This study is recruiting.

Who is eligible?

• Children 2 to <18 years.